Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06545734

Effectiveness and Biological Mechanism of Direct Ischemic Post-conditioning for Acute Stroke Patients Due to Large Vessel Occlusion

Effectiveness and Biological Mechanism of Direct Ischemic Post-conditioning for Acute Stroke Patients Due to Large Vessel Occlusion: A Randomized Controlled Pilot Trial

Status
Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
Tianjin Huanhu Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The goal of this clinical trial is to determine if direct ischemic post-conditioning (IPostC) can alleviate ischemic-reperfusion injury (I/R) in patients who have undergone endovascular thrombectomy (EVT). Additionally, the study aims to explore the underlying mechanisms of direct IPostC. The primary questions this trial seeks to answer are: 1. Is direct IPostC effective for acute stroke patients with large vessel occlusion? 2. What are the underlying mechanisms of direct IPostC? Participants will be randomly assigned to one of two groups: an EVT alone group or an EVT plus direct IPostC group. Direct IPostC will be administered immediately after EVT through four cycles of mechanical interruptions of reperfusion. We will evaluate outcomes based on final infarct volume, infarct volume growth, clinical parameters, and I/R-related imaging and laboratory biomarkers. Additionally, an exploratory multi-omics analysis will be conducted to uncover the detailed mechanisms of direct IPostC.

Conditions

Interventions

TypeNameDescription
PROCEDUREDirect Ischemic Post-conditioningAfter thrombectomy, the balloon was inflated to a pressure of no more than 4 atm at the occlusion site to block blood flow for 2 minutes, as confirmed by angiography. The balloon was then deflated, allowing blood flow to resume for 2 minutes. These steps were repeated four times.
PROCEDUREEndovascular therapyThrombectomy alone.

Timeline

Start date
2023-02-05
Primary completion
2024-09-01
Completion
2024-09-01
First posted
2024-08-09
Last updated
2024-08-09

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06545734. Inclusion in this directory is not an endorsement.